Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2021-01-04 M&A Activity
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Atacand divestment in over 70 countries completed
M&A Activity Classification · 99% confidence The document is very short (3756 characters) and contains the header 'RNS Number : 3967K' and concludes with information about RNS, the news service of the London Stock Exchange. The content announces the completion of a divestment and provides financial details related to that transaction. This structure strongly suggests a regulatory news service announcement rather than a comprehensive report (like 10-K or IR). Since it is a general regulatory announcement distributed via RNS and doesn't fit specific categories like Capital Change (SHA) or M&A (TAR), the most appropriate classification is the general Regulatory Filings category (RNS).
2021-01-04 English
ASTRAZENECA'S COVID-19 VACCINE AUTHORISED IN UK
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, submitted to the SEC as a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It announces the emergency authorization of AstraZeneca's COVID-19 vaccine in the UK, including details about regulatory approval, clinical trial data, and manufacturing plans. The document is an announcement of significant company news rather than a full financial report or detailed financial statements. It does not contain comprehensive financial data or management discussion typical of annual or interim reports. It is also not a transcript, proxy, or governance document. Given the nature of the content and the form type (6-K), this filing fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-12-30 English
AstraZeneca’s COVID-19 vaccine authorised in UK
Regulatory Filings Classification · 99% confidence The document is identified by the header 'RNS Number : 1114K' and contains a date stamp typical of regulatory news services. The content announces the emergency supply authorisation of AstraZeneca's COVID-19 vaccine by the UK Medicines and Healthcare products Regulatory Agency (MHRA). This is a time-sensitive, material announcement released via RNS (Regulatory News Service). Since it is a general regulatory announcement that doesn't fit neatly into specific financial report categories (like 10-K, ER, or IR), and it is clearly distributed through the RNS system, the most appropriate classification is Regulatory Filings (RNS). The document length is substantial (9075 chars), but its nature is that of a formal regulatory disclosure rather than a comprehensive financial report.
2020-12-30 English
LYNPARZA APPROVED IN JAPAN FOR THE TREATMENT OF ADVANCED OVARIAN, PROSTATE AND P
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the announcement of regulatory approval of Lynparza in Japan for treatment of various cancers, detailing clinical trial results and drug information. It is an announcement of a significant corporate event related to product approval rather than a financial report, earnings release, or management discussion. The document is not an annual or interim report, audit report, or earnings release. It is a regulatory filing reporting material information to the SEC about the company's operations and approvals. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it contains detailed information, not just a brief announcement or certification, supporting this classification with high confidence.
2020-12-29 English
Lynparza approved in Japan for three cancers
Regulatory Filings Classification · 100% confidence The document is an official announcement from AstraZeneca PLC, identified by the RNS Number (Regulatory News Service) and the date stamp (29 December 2020 07:00 GMT). The content details the approval of the drug Lynparza in Japan for several cancer treatments, citing specific Phase III trials (PAOLA-1, PROfound, POLO) and providing extensive clinical and background information on the drug and the company's strategy. This is a significant corporate event announcement related to product development and regulatory milestones, which typically falls under general regulatory news or investor relations updates. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management/board change, the most appropriate classification is Regulatory Filings (RNS), as it is a formal announcement disseminated via the RNS system regarding a material event.
2020-12-29 English
TAGRISSO APPROVED IN THE US FOR THE ADJUVANT TREATMENT OF PATIENTS WITH EARLY-ST
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains a detailed announcement about the FDA approval of Tagrisso for adjuvant treatment in early-stage EGFR-mutated lung cancer, including clinical trial results, regulatory review processes, and company information. The document is not a full annual or interim financial report, nor is it a transcript, audit, or management report. It is a regulatory filing providing material information about a significant corporate event (drug approval) but does not fit into other specific categories like earnings release or capital update. The length (13,882 characters) and content indicate it is a substantive regulatory announcement rather than a brief notice or certification. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-12-21 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.